Yahoo Web Search

Search results

1. Top stories

   • 

     Billionaire Harvard Professor’s Fortune Jumps Nearly $200 Million On News Of Eli Lilly Biotech Deal

     Shares of biotech firm Morphic Holding, founded by Harvard immunologist Tim Springer, rocketed up 75% Monday after Eli Lilly said it would snap it up for $3.2 billion.

     Forbes

     49 minutes ago

   • 

     Forbes on MSN.com

     Eli Lilly Buys Bowel Disease Drug Developer Morphic In $3.2 Billion Deal

     6 hours ago

   • 

     Seeking Alpha

     Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal

     3 hours ago

   • 

     Invezz

     Eli Lilly to buy biopharma company Morphic in $3.2 billion deal

     6 hours ago

   • WIBC

     Eli Lilly Acquiring Biopharmaceutical Company Morphic

     1 hour ago

   View all

2. www.lilly.com › newsAll News | Eli Lilly and Company

   www.lilly.com › news

   Lilly's latest press releases, stories, news resources and more.

   • Lilly.com | Eli Lilly and Company

     INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and...

   • Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the ...

     INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and...

   • Lilly to Acquire Versanis to Improve Patient Outcomes in ...

     The company's lead asset, bimagrumab, is being advanced in...

3. www.lilly.com › news › press-releasesLilly.com | Eli Lilly and Company

   www.lilly.com › news › press-releases

   INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.

4. www.reuters.com › business › healthcareLilly hits record high after Mounjaro fuels forecast raise ...

   www.reuters.com › business › healthcare

   Aug 8, 2023 · Aug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares...

5. www.bloomberg.com › news › articlesEli Lilly (LLY) Agrees to Buy US Biotech Morphic (MORF) in $3 ...

   www.bloomberg.com › news › articles

   • Cached

   8 hours ago · Eli Lilly & Co. agreed to buy U.S. gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some of the proceeds from obesity blockbuster Zepbound into its experimental pipeline.

6. investor.lilly.com › news-releases › news-releaseLilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the ...

   investor.lilly.com › news-releases › news-release

   • Cached

   6 days ago · INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia ...

7. investor.lilly.com › news-releases › news-releaseLilly to Acquire Versanis to Improve Patient Outcomes in ...

   investor.lilly.com › news-releases › news-release

   • Cached

   Jul 14, 2023 · The company's lead asset, bimagrumab, is being advanced in the BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. Versanis was founded in 2021 by Aditum Bio. For more information, please visit www.versanisbio.com. About Lilly

8. People also ask

   Why did Eli Lilly raise its annual forecasts?

   • REUTERS/Mike Segar/File Photo Purchase Licensing Rights Aug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record high also helped by positive data from a rival drug.

   Lilly hits record high after Mounjaro fuels forecast raise, rival data

   www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-beats-profit-estimates-strength-new-diabetes-drug-2023-08-08/

   See all results for this question

   Will Eli Lilly pay a dividend in 2024?

   • Antimicrobial resistance (AMR) is one of the top public INDIANAPOLIS , June 24, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on Sept. 10, 2024 , to shareholders of record at the close of

   Lilly.com | Eli Lilly and Company

   www.lilly.com/news/press-releases

   See all results for this question

   Does Eli Lilly treat diabetes and obesity?

   • Eli Lilly and Company is committed to meeting the needs of people living with diabetes and obesity with treatment options that change the way healthcare providers can treat these diseases. Today, we are publishing an open lette r to ensure that people living with diabetes and obesity, their

   Lilly.com | Eli Lilly and Company

   www.lilly.com/news/press-releases

   See all results for this question

   Is Eli Lilly acquiring versanis bio?

   • INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

   Lilly to Acquire Versanis to Improve Patient Outcomes in

   investor.lilly.com/news-releases/news-release-details/lilly-acquire-versanis-improve-patient-outcomes-cardiometabolic

   See all results for this question

9. www.reuters.com › business › healthcareLilly drug slows Alzheimer's by 35%, bolstering treatment ...

   www.reuters.com › business › healthcare

   May 8, 2023 · An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest...